Complete Information on Angiosarcoma of the Breast With Treatment and Prevention

Angiosarcoma of the breast is an uncommon, extremely hostile neoplasm of vascular origin. Angiosarcomas are aggressive and tend to recur locally, spread widely, and have a high rate of lymph node and systemic metastases. The rate of tumor-related death is high. Angiosarcomas also can originate in the liver, breast, spleen, bone, or heart. Secondary angiosarcomas usually occur in older women years following the treatment of breast cancer. They can arise in the lymphedemateous upper extremity years following radical mastectomy and irradiation. Secondary angiosarcomas can also arise in the chest wall following mastectomy and irradiation, or in the breast following breast conserving therapy. The etiology of most cases of angiosarcoma is unknown. The tumors may develop as a complication of a preexisting condition. Some angiosarcomas are associated with foreign material introduced in the body, either iatrogenically or accidentally.

Angiosarcomas are pernicious, and they may not develop symptoms until the disease is easily advanced. All angiosarcomas lean to be competitive and frequently are multicentric. These tumors have a higher local recurrence pace and metastasis because of their inherent biologic properties and because they frequently are misdiagnosed, leading to an impoverished prognosis and a higher mortality pace. Making the diagnosis of post-irradiation angiosarcoma can be hard. High class angiosarcomas can be well confused with new cancerous tumors such as recurrent andenocarcinoma, lymphoma, and melanoma. Angiosarcomas may submit in a kind of manners. They may get a show suggesting transmission, bruising, tender tissue people, or a blood vessel like lesion. Angiosarcomas are seldom associated with leading vessels, and are rare in children.

Clinical features are varying. Angiosarcomas can happen in any area of the system, although they are almost usually located in the rind, bosom, liver, and profound tissue. Cutaneous angiosarcomas, which are angiosarcomas of the rind, are usually establish in the cheek and scalp area. The initial symptoms normally are chest pain, hemoptysis, weight departure, coughing, and dyspnea. However, some patients are asymptomatic. Occasionally, the tumors are characterized with chronic edema and alleged cellulites. Skin erythema, another popular earlier finding, is frequently confused with transmission. The initial presenting findings can too be confused with post-irradiation changes. Less popular presenting findings include eczematoid changes, ulcerations, violent nipple release, and non-pigmented macules. Patients can be asymptomatic for a lengthy moment or they can submit with symptoms mimicking intense pericarditis, pulmonary embolism, or tricuspid stenosis.

Standard handling for post-irradiation angiosarcoma is overall mastectomy which is normally followed by latissimus flaps shutdown. Regional lymph node metastasis are uncommon. Angiosarcomas may submit without an inciting reason, in chronically lymphedematous limbs, or in areas previously treated or exposed to radioactivity. Multiple randomized studies using doxorubicin-based chemotherapy break to indicate an endurance welfare, although metaanalysis suggests improved local command and disease-free endurance with chemotherapy, but no endurance reward. Breast angiosarcoma is better treated with a combination of radiation and chemotherapy to attain local command. In some patients, mastectomy may be region of this handling plan. In locally advanced cases hyperfractionated theray may be given prior to postoperative resection.

St. Jude Unlocks Mystery of Very Aggressive Leukemia

- Loss of Arf gene in acute lymphoblastic leukemia makes some forms of this cancer resistant to treatment with imatinib, but blocking JAK kinases can restore the sensitivity of cells to this drug

Investigators at St. Jude have used mouse models to determine why some forms of acute lymphoblastic leukemia (ALL) are very aggressive and resistant to a drug that is effective in treating a different type of leukemia.

The investigators found that the combination of a mutation called Bcr-Abl and the loss of both copies of the tumor suppressor gene Arf in bone marrow cells triggers an aggressive form of ALL. Inactivation of both Arf genes allowed the multiplication of leukemic cells that did not respond to the drug imatinib (Gleevec®). Imatinib is already successfully used to treat chronic myelogenous leukemia (CML), another blood cell cancer caused by the Bcr-Abl mutation.

The St. Jude team also found that Arf is not inactivated in CML patients who respond to imatinib. This is in contrast to ALL, in which Arf loss frequently occurs and imatinib treatment is far less effective. “This suggested to us that inactivation of Arf in ALL cells expressing the Bcr-Abl enzyme gives these cells a strong proliferative (cell multiplication) advantage. This advantage might contribute to imatinib resistance in some way,” said Charles Sherr, M.D., Ph.D., a Howard Hughes Medical Institute Investigator and co-chair of the St. Jude Department of Genetics and Tumor Cell Biology. Sherr is senior author of a report on this work that appears in the April 17 issue of the Proceedings of the National Academy of Sciences.

The Arf gene was discovered at St. Jude in 1995 in the laboratory of Sherr and Martine Roussel, Ph.D., a member of the Department of Genetics and Tumor Cell Biology. Roussel is a co-author of the paper.

Moreover, the study provided evidence that imatinib resistance in mouse models of ALL did not depend strictly on the presence of Bcr-Abl and the loss of Arf genes in the cancer cells themselves. Rather, drug resistance reflected an interaction of the tumor cells with specific growth-promoting factors produced in the mice. After removal of leukemic cells from mice that had failed imatinib therapy, compounds that inhibited enzymes called JAK kinases restored the cells’ sensitivity to imatinib.

The findings of this study are important because they suggest why imatinib may fail to cause remission of ALL in patients with the Bcr-Abl mutation, and they point to a strategy for overcoming this resistance, according to the researchers. “Although our efforts to block JAK enzymes were limited to cell cultures, our mouse model provides an inexpensive and efficient way to test newly developed JAK kinase inhibitors and other drugs,” said Richard Williams, M.D., PhD, a research fellow in Sherr’s laboratory and the lead author of the paper.

This work was supported in part by the Howard Hughes Medical Institute, a National Institutes of Health Cancer Center Core Grant and ALSAC.

About: St. Jude Children’s Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization.